FACTORS ASSOCIATED WITH BLEEDING EVENTS FROM LOW MOLECULAR WEIGHT HEPARIN USED IN ACUTE CORONARY SYNDROME PATIENTS

FACTORS ASSOCIATED WITH BLEEDING EVENTS FROM LOW MOLECULAR WEIGHT HEPARIN USED IN ACUTE CORONARY SYNDROME PATIENTS AT KING CHULALONGKORN MEMORIAL HOSPITAL

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20171225002

Enrollment

783

Registered

2017-12-25

Start date

2018-03-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BLEEDING EVENTS FROM LOW MOLECULAR WEIGHT HEPARIN USED IN ACUTE CORONARY SYNDROME PATIENTS Bleeding&#44

Interventions

Acute coronary syndrome patients who receive low molecular weight heparin

Screening

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age > 18 years. 2. Diagnosis of Acute coronary syndrome. (Unstable angina,non ST elevation myocardial infarction, ST elevation myocardial infarction) 3. Received at least one dose of low molecular weight heparin. (enoxaparin 1 mg/kg by subcutaneous injection)

Exclusion criteria

Exclusion criteria: 1. Received thrombolytics or GP IIb/IIIa inhibitors. 2. Received unfractionated heparin after treatment with low molecular weight heparin. 3. Patients information from medical records not complete for follow up bleeding events.

Design outcomes

Primary

Measure	Time frame
Bleeding events associated with low molecular weight heparin In 30 days first bleeding event after start low molecular weight heparin	—

Secondary

Measure	Time frame
None none none	—

Countries

Thailand

Contacts

Public ContactAdisak Weerasaksanti

Faculty of Pharmaceutical Sciences, Chulalongkorn University

Adisakwee@hotmail.com081-443-6503

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026